Treatment strategy for pancreatic endocrine tumours;Stratégies thérapeutiques des tumeurs endocrines pancréatiques

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 3 SUPPL., 2003, Pages

  Mitry, Emmanuel ^a   Rougier, Philippe ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CHLOROZOTOCIN; CHROMOGRANIN A; CISPLATIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; OCTREOTIDE; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; DRUG DERIVATIVE; INTERFERON; SOMATOSTATIN;

ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CONFERENCE PAPER; ENDOCRINE PANCREAS FUNCTION TEST; ENDOCRINE TUMOR; EVALUATION; HUMAN; PANCREAS TUMOR; SYMPTOMATOLOGY; METHODOLOGY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EMBOLIZATION, THERAPEUTIC; ENDOCRINE GLAND NEOPLASMS; HUMANS; INTERFERONS; PANCREATIC NEOPLASMS; SOMATOSTATIN;

EID: 0038406187     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Fléjou JF et al. Prognostic factors in patients with endocrine tumours of the duodeno-pancreatic area. Gut 1998;43:422-7.
2. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633-42.
3. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999;17:615-30.
4. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001;12:1295-300.
5. Ruszniewski P. Analogues de la somatostatine au cours des tumeurs neuro-endocrines digestives (tumeurs carcinoïdes et tumeurs endocrines du pancréas). In: Rougier P, ed. Tumeurs neuro-endocrines malignes. París: Arnette; 1997:93-7.
6. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000;62 Suppl 1:84-91.
7. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992;13:27-35.
8. Lasser P, Elias D, Bonvalot S, Ducreux M, Rougier P. Traitements locaux-régionaux des tumeurs neuro-endocrines malignes. In: Rougier P, ed. Tumeurs neuro-endocrines malignes. Paris: Arnette; 1997:67-81.
9. Eriksson B, Oberg K. Neuroendocrine tumours of the pancreas. Br J Surg 2000;87:129-31.
10. Jaeck D, Oussoultzoglou E, Bachellier P, Lemarque P, Weber JC, Nakano H et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001;25:689-92.
11. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36-42.
12. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992;112:1024-31.
13. Elias D, Rougier P, Lasser P, Duvillard P, Venezia P, Schlumberger M et al. Chirurgie majeure et chimiothérapie réductionnelle dans les apudomes métastatiques. Ann Chir 1988;42:474-81.
14. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001;25:693-6.
15. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20:908-14.
16. Corleto VD, Panzuto F, Falconi M, Cannizzaro R, Angeletti S, Moretti A et al. Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2001;33:217-21.
17. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:108-18.
18. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502-22.
19. Moertel CG, Lavin PT, Hahn RG. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1982;66:1567-9.
20. Altimari AF, Badrinath K, Reisel HJ, Prinz RA. DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery 1987;102:1009-17.
21. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998;21:36-8.
22. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;83:372-8.
23. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002;13:614-21.
24. Rougier P, Oliveira J, Ducreux M, Theodore C, Kac J, Droz JP. Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. Eur J Cancer 1991;27:1380-2.
25. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189-94.
26. Moertel CG, Letkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
27. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-8.
28. Boige V, Delaunoit T, Baudin E, Dromain C, Lebray P, Lassau N et al. Efficacité de l'association adriamycine-streptozotocine (A-S) dans le traitement des tumeurs neuroendocrines du pancréas (TNEP): étude des facteurs prédictifs de réponse et de survie. Gastroenterol Clin Biol 2002;26,HS1:0399-8320.
29. Ruszniewski P, Hammel P, Tigaud J, Maire F, O'Toole D, Lévy P. Chimiothérapie systémique chez les malades atteints de tumeurs endocrines digestives (TED): une efficacité à réviser. Gastroenterol Clin Biol 2002;26,HS1.
30. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-8.
31. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000;11:1127-30.
32. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-81.
33. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-9.
34. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-6.
35. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, van Cutsem EJ, Fiasse RH et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111.
36. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002;94:331-43.
37. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-83.
38. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653-68.
39. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5.
40. Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M et al. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. Eur J Cancer 1992;28A:1664-6.
41. Saltz L, Kemeny N, Schwartz G, Kelsen D. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994;74:958-61.
42. Oberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep 1986;70:1297-304.
43. Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours. Digestion 1996;57 Suppl 1:84-5.
44. Janson ET, Ronnblom L, Ahlstrom H, Grander D, Alm G, Einhorn S et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992;3:635-8.
45. Hughes MJ, Kerr DJ, Cassidy J, Soukop M, McGregor K, Blackburn N et al. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours. Ann Oncol 1996;7:208-10.
46. Andreyev HJ, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995;13:1486-92.
47. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-7.
48. Faiss S, Riecken EO, Wiedenmann B, Franklin B. Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon-alpha and the combination for therapy of metastatic neuroendocrine GEP-tumors (abstract). Proc Am Soc Clin Oncol 2000;19:1014.
49. Sjoblom SM, Hockerstedt K, Jarvinen H. Hepatic dearterialization in the treatment of carcinoid syndrome. Acta Chir Scand 1987;153:523-9.
50. Mitty HA, Warner RR, Newman LH, Train JS, Parnes IH. Control of carcinoid syndrome with hepatic artery-embolization. Radiology 1985;155:623-6.
51. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986;147:149-54.
52. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988;108:340-4.
53. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293-301.
54. Moertel CG, Johnson CM, McKusick MA, Martin JK, Jr., Nagorney DM, Kvols LK et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
55. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71:2624-30.
56. Therasse E, Breittmayer F, Roche A, De Baere T, Indushekar S, Ducreux M et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993;189:541-7.
57. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999;17:474-8.
58. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
59. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
60. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000;23:412-5.
61. Seitz J, Perrier H, Giovannini M, Monges G, Fourdan O, Barrière N et al. Cancers neuroendocrines anaplasiques avancés: intérêt de l'association VP16-CDDP. Bull Cancer 1995;82:433.